✨Exciting to see clinical efficacy of peripheral #CB1R antagonism with #monlunabant. It will expand armamentarium for #obesity with an oral 💊therapy and a different mechanism than incretins ( #GLP1 #GIP)💉
⚡️Similar efficacies in all tested oral doses encourage testing lower doses to optimize safety.
⚡️Similar efficacies in all tested oral doses encourage testing lower doses to optimize safety.
The implications of this trial, combined with existing evidence, suggest that #monlunabant has potential as a novel treatment option for people with #obesity and #metabolic #syndrome, if a safe and effective therapeutic window can be established www.thelancet.com/journals/lan...
#MedSky #EndoSky
#MedSky #EndoSky
October 9, 2025 at 1:53 AM
✨Exciting to see clinical efficacy of peripheral #CB1R antagonism with #monlunabant. It will expand armamentarium for #obesity with an oral 💊therapy and a different mechanism than incretins ( #GLP1 #GIP)💉
⚡️Similar efficacies in all tested oral doses encourage testing lower doses to optimize safety.
⚡️Similar efficacies in all tested oral doses encourage testing lower doses to optimize safety.
DESPUÉS DE GRANDES ÉXITOS COMO EL RIMONOBANT VOLVEMOS A INTENTARLO CON EL MONLUNABANT
Abro hilo.
Abro hilo.
October 6, 2025 at 3:36 PM
DESPUÉS DE GRANDES ÉXITOS COMO EL RIMONOBANT VOLVEMOS A INTENTARLO CON EL MONLUNABANT
Abro hilo.
Abro hilo.
Kishore M Gadde & colleagues comment on:
Peripheral CB1 receptor blockade for treatment of obesity www.thelancet.com/journals/lan...
#monlunabant #obesity #metabolic #syndrome
#MedSky #EndoSky
Peripheral CB1 receptor blockade for treatment of obesity www.thelancet.com/journals/lan...
#monlunabant #obesity #metabolic #syndrome
#MedSky #EndoSky
Peripheral CB1 receptor blockade for treatment of obesity
The endocannabinoid system—comprising cannabinoid receptors (CB1 and CB2), lipid-derived
ligands, and metabolic enzymes—plays a major role in regulating energy homoeostasis.1
CB1 receptors are abundan...
www.thelancet.com
October 4, 2025 at 8:09 AM
Kishore M Gadde & colleagues comment on:
Peripheral CB1 receptor blockade for treatment of obesity www.thelancet.com/journals/lan...
#monlunabant #obesity #metabolic #syndrome
#MedSky #EndoSky
Peripheral CB1 receptor blockade for treatment of obesity www.thelancet.com/journals/lan...
#monlunabant #obesity #metabolic #syndrome
#MedSky #EndoSky
The implications of this trial, combined with existing evidence, suggest that #monlunabant has potential as a novel treatment option for people with #obesity and #metabolic #syndrome, if a safe and effective therapeutic window can be established www.thelancet.com/journals/lan...
#MedSky #EndoSky
#MedSky #EndoSky
October 4, 2025 at 8:09 AM
The implications of this trial, combined with existing evidence, suggest that #monlunabant has potential as a novel treatment option for people with #obesity and #metabolic #syndrome, if a safe and effective therapeutic window can be established www.thelancet.com/journals/lan...
#MedSky #EndoSky
#MedSky #EndoSky
New—Efficacy and safety of #monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial thelancet.com/journals/lan...
#obesity #MetabolicSyndrome
#MedSky #EndoSky
#obesity #MetabolicSyndrome
#MedSky #EndoSky
Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial
Participants receiving monlunabant showed statistically significant and clinically
meaningful weight loss compared with those receiving placebo for all tested doses.
Only slightly greater weight loss ...
thelancet.com
September 29, 2025 at 10:38 PM
New—Efficacy and safety of #monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial thelancet.com/journals/lan...
#obesity #MetabolicSyndrome
#MedSky #EndoSky
#obesity #MetabolicSyndrome
#MedSky #EndoSky
SDBN Trending: Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model https://zpr.io/VhRg5ky7GDSn
September 4, 2025 at 9:22 PM
SDBN Trending: Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model https://zpr.io/VhRg5ky7GDSn
$SKYE reported preclinical data showing >30% weight loss in a DIO mouse model when its CB1 antibody nimacimab was combined with tirzepatide; nimacimab alone showed 23.5% weight loss on par with monlunabant and tirzepatide monotherapy
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/mu...
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/mu...
April 15, 2025 at 8:53 PM
$SKYE reported preclinical data showing >30% weight loss in a DIO mouse model when its CB1 antibody nimacimab was combined with tirzepatide; nimacimab alone showed 23.5% weight loss on par with monlunabant and tirzepatide monotherapy
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/mu...
See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/mu...
Novo Nordisk Financial Report Reveals Monlunabant Failure But Several Bright Spots for ... - goo.gl/alerts/on17wb #GoogleAlerts
Novo Nordisk Financial Report Reveals Monlunabant Failure But Several Bright Spots for Kidney Diseas | Docwire News
Monlunabant failed in a study of its use in diabetic kidney disease (DKD), but Novo Nordisk had positive news about other kidney treatments in its 2024 financial report.
goo.gl
February 8, 2025 at 4:51 PM
Novo Nordisk Financial Report Reveals Monlunabant Failure But Several Bright Spots for ... - goo.gl/alerts/on17wb #GoogleAlerts
A study of DKD drug monlunabant failed to meet its primary endpoint, but not all the kidney disease news in Novo Nordisk's 2024 financial report was bleak. #NovoNordisk #kidneydisease #diabetickidneydisease #drugdevelopment #nephrology #nephsky
Novo Nordisk Financial Report Reveals Monlunabant Failure But Several Bright Spots for Kidney Diseas | Docwire News
Monlunabant failed in a study of its use in diabetic kidney disease (DKD), but Novo Nordisk had positive news about other kidney treatments in its 2024 financial report.
buff.ly
February 7, 2025 at 5:15 PM
A study of DKD drug monlunabant failed to meet its primary endpoint, but not all the kidney disease news in Novo Nordisk's 2024 financial report was bleak. #NovoNordisk #kidneydisease #diabetickidneydisease #drugdevelopment #nephrology #nephsky
Not every drug works. In this case, it was monlunabant (and the outcome was UACR).
www.fiercebiotech.com/biotech/novo...
www.fiercebiotech.com/biotech/novo...
Novo flunks kidney disease trial, again linking obesity prospect to neuropsychiatric side effects
Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. | Novo Nordisk’s cannabinoid CB1 receptor blocker has run into another problem. Months after sharing obesity data that lef...
www.fiercebiotech.com
February 5, 2025 at 9:19 PM
Not every drug works. In this case, it was monlunabant (and the outcome was UACR).
www.fiercebiotech.com/biotech/novo...
www.fiercebiotech.com/biotech/novo...
Just In: ( NASDAQ: #SKYE ) Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan
#StockMarket #News
#StockMarket #News
September 23, 2024 at 2:30 PM
Based on its NYSE move, Novo Nordisk has shed ~$34b in m/cap following the "successful" completion of a Phase IIa study of CB1 reverse agonist monlunabant. Efficacy underwhelming; neuropsychiatric effects troubling. Corbus CRBP also down. #biosky #biotech www.globenewswire.com/news-release...
Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral...
www.globenewswire.com
September 20, 2024 at 2:47 PM
Based on its NYSE move, Novo Nordisk has shed ~$34b in m/cap following the "successful" completion of a Phase IIa study of CB1 reverse agonist monlunabant. Efficacy underwhelming; neuropsychiatric effects troubling. Corbus CRBP also down. #biosky #biotech www.globenewswire.com/news-release...